How Is Acrux Leveraging FDA Wins to Expand US and Hormone Therapy Markets?

middle.news 9:04am on Thursday 29th of January, 2026 AEDT • Healthcare Read Story

How Is Acrux Leveraging FDA Wins to Expand US and Hormone Therapy Markets?

9:04am on Thursday 29th of January, 2026 AEDT Key Points Receipts from customers rose to $1.807 million in December quarter Cash and cash equivalents increased to $0.946 million Divestment of underperforming Prilocaine and Lidocaine creams for $0.822 million Expansion of topical generics portfolio in US, notably Dapsone 7.5% Gel Read Story

middle. Tap to Read Tap the card to read the full analysis about ACRUX (ASX:ACR) OPEN ARTICLE